AngioDynamics beats top-line and bottom-line estimates; reaffirms FY26 outlook

• AngioDynamics press release (ANGO): Q1 Non-GAAP EPS of -$0.04 beats by $0.07.
• Revenue of $80.92M (+6.9% Y/Y) beats by $0.42M.
• Med Device net sales were $41.0 million, a 1.4% increase compared to $40.4 million in the prior-year period.
• Adjusted EBITDA in the first quarter of fiscal 2027, excluding the items shown in the non-GAAP reconciliation table below, was $5.0 million, compared to $2.2 million in the first quarter of fiscal 2026.

• In the first quarter of fiscal 2027, the company used $15.3 million of cash from operations, compared to $15.9 million in the first quarter of fiscal 2026.

• At August 31, 2026, the company had $34.0 million in cash and maintains a debt-free balance sheet.

• Fiscal Year 2027 Financial Guidance

  Based on its first quarter performance and current outlook for the remainder of the fiscal year, the Company is reiterating its previously issued fiscal year 2027 guidance, as outlined below.

  Guidance Metric	Guidance (As of October 8, 2026)
  Net Sales	$336.0M - $341.0M vs. consensus of $337.33M
  Med Tech Net Sales Growth	12% – 15%
  Med Device Net Sales Growth	Flat
  Gross Margin	54% – 55%
  Adjusted EBITDA	$13.0M - $16.0M
  Adjusted EPS	($0.29) – ($0.24) vs. consensus of -$0.27

Recommended For You

Register for free to keep reading.

Create a free account to get unlimited breaking news and alerts when your stocks move.